Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Sep;104(1):246–250. doi: 10.1111/j.1476-5381.1991.tb12414.x

Evidence against a role for dopamine D1 receptors in the myocardium of the pig.

L J Van Woerkens 1, D J Duncker 1, M O Den Boer 1, E O McFalls 1, L M Sassen 1, P R Saxena 1, P D Verdouw 1
PMCID: PMC1908288  PMID: 1686206

Abstract

1. We investigated the presence of dopamine D1 receptors in the myocardium of anesthetized pigs using intravenous infusions of dopamine, alone and after alpha- and beta-adrenoceptor blockade and intracoronary infusions of the selective D1 receptor agonist, fenoldopam. 2. Intravenous infusion of dopamine (2.5, 5 and 10 micrograms kg-1 min-1 for 10 min, n = 6) caused dose-dependent changes in heart rate (from 94 +/- 6 to 132 +/- 10 beats min-1, P less than 0.05), the maximal rate of rise of left ventricular pressure (LVdP/dtmax; from 2280 +/- 170 to 4800 +/- 410 mmHgs-1, P less than 0.05), mean arterial blood pressure (from 87 +/- 5 to 62 +/- 3 mmHg) and systemic vascular resistance (from 40 +/- 4 to 28 +/- 2 mmHgl-1 min, P less than 0.05). The increases in heart rate and LVdP/dtmax were abolished when dopamine was infused after alpha- and beta-adrenoceptor blockade. The vasodilator response was, however, only minimally affected. 3. Intravenous infusions of dopamine decreased coronary vascular resistance from 0.90 +/- 0.06 to 0.53 +/- 0.07 mmHg ml-1 min 100 g (P less than 0.05). This action of dopamine was not observed when dopamine was infused after blockade of the alpha- and beta-adrenoceptors. 4. Pretreatment with alpha- and beta-adrenoceptor blockade had no effect or only slightly attenuated the dopamine-induced decrease in vascular resistance of the brain, kidneys, adrenals and small intestine.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
246

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Duncker D. J., van Dalen F. J., Hartog J. M., Lamers J. M., Rensen R. J., Saxena P. R., Verdouw P. D. Usefulness of pimobendan in the treatment of heart failure. Arzneimittelforschung. 1986 Dec;36(12):1740–1744. [PubMed] [Google Scholar]
  2. Goldberg L. I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev. 1972 Mar;24(1):1–29. [PubMed] [Google Scholar]
  3. Gootman N., Buckley B. J., Gootman P. M., Griswold P. G., Mele J. D., Nudel D. B. Maturation-related differences in regional circulatory effects of dopamine infusion in swine. Dev Pharmacol Ther. 1983;6(1):9–22. doi: 10.1159/000457273. [DOI] [PubMed] [Google Scholar]
  4. Hieble J. P., Owen D. A., Harvey C. A., Blumberg A. L., Valocik R. E., DeMarinis R. M. Hemodynamic effects of selective dopamine receptor agonists in the rat and dog. Clin Exp Hypertens A. 1987;9(5-6):889–912. doi: 10.3109/10641968709161456. [DOI] [PubMed] [Google Scholar]
  5. Hughes A. D., Sever P. S. Action of fenoldopam, a selective dopamine (DA1) receptor agonist, on isolated human arteries. Blood Vessels. 1989;26(2):119–127. doi: 10.1159/000158760. [DOI] [PubMed] [Google Scholar]
  6. Kopia G. A., Valocik R. E. Demonstration of specific dopamine-1 receptor-mediated coronary vasodilation in the anesthetized dog. J Pharmacol Exp Ther. 1989 Jan;248(1):215–221. [PubMed] [Google Scholar]
  7. Niemegeers C. J., Van Nueten J. M., Janssen P. A. Azaperone, a sedative neuroleptic of the butyrophenone series with pronounced anti-aggressive and anti-shock activity in animals. Arzneimittelforschung. 1974 Nov;24(11):1798–1806. [PubMed] [Google Scholar]
  8. Sassen L. M., Duncker D. J., Gho B. C., Diekmann H. W., Verdouw P. D. Haemodynamic profile of the potassium channel activator EMD 52692 in anaesthetized pigs. Br J Pharmacol. 1990 Nov;101(3):605–614. doi: 10.1111/j.1476-5381.1990.tb14128.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Sassen L. M., Soei L. K., Koning M. M., Verdouw P. D. The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs. Br J Pharmacol. 1990 Feb;99(2):355–363. doi: 10.1111/j.1476-5381.1990.tb14708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Saxena P. R., Schamhardt H. C., Forsyth R. P., Hoeve J. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed. 1980 Dec;12(2-3):63–84. doi: 10.1016/0010-468x(80)90053-7. [DOI] [PubMed] [Google Scholar]
  11. Schuelke D. M., Mark A. L., Schmid P. G., Eckstein J. W. Coronary vasodilatation produced by dopamine after adrenergic blockade. J Pharmacol Exp Ther. 1971 Feb;176(2):320–327. [PubMed] [Google Scholar]
  12. Toda N. Dopamine vasodilates human cerebral artery. Experientia. 1983 Oct 15;39(10):1131–1132. doi: 10.1007/BF01943144. [DOI] [PubMed] [Google Scholar]
  13. Toda N., Hatano Y. Antagonism by droperidol of dopamine-induced relaxation in isolated dog arteries. Eur J Pharmacol. 1979 Aug 1;57(2-3):231–238. doi: 10.1016/0014-2999(79)90370-4. [DOI] [PubMed] [Google Scholar]
  14. Ueda S., Yano S., Sakanashi M. In vitro evidence for dopaminergic receptors in human renal artery. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):76–81. doi: 10.1097/00005344-198201000-00013. [DOI] [PubMed] [Google Scholar]
  15. Verdouw P. D., Sassen L. M., Duncker D. J., Schmeets I. O., Rensen R. J., Saxena P. R. Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs. Naunyn Schmiedebergs Arch Pharmacol. 1987 Sep;336(3):352–358. doi: 10.1007/BF00172690. [DOI] [PubMed] [Google Scholar]
  16. Zhao R. R., Fennell W. H., Abel F. L. Effects of dopamine D1 and dopamine D2 receptor agonists on coronary and peripheral hemodynamics. Eur J Pharmacol. 1990 Nov 6;190(1-2):193–202. doi: 10.1016/0014-2999(90)94126-i. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES